

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Transcenta Holding Limited

創勝集團醫藥有限公司

(registered by way of continuation in the Cayman Islands with limited liability)

(Stock code: 6628)

**(1) CHANGE OF STOCK SHORT NAME;
AND
(2) CHANGE OF COMPANY LOGO**

CHANGE OF STOCK SHORT NAME

The board of directors (the “**Board**”) of Transcenta Holding Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that the stock short name of the Company in Chinese for trading in the shares on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) will be changed from “創勝集團-B” to “創勝集團醫藥-B” with effect from 9:00 a.m. on 13 April 2026. The stock short name in English, the name of the Company and the stock code of the Company on the Stock Exchange remains unchanged.

This action will clearly articulate the Company’s unwavering commitment to focusing on the biopharmaceutical sector, and more accurately reflect the Company’s core business and future development strategy centered on the integrated capabilities of the Company based on its three key technology platforms for drug discovery (IMTB), CMC process development and GMP manufacturing (HiCB), and development of site specifically conjugated engineered antibody radiopharmaceuticals (SEAR). The Company is focused on the global development and commercialization of leading biologics assets, including osemitamab (TST001) for the treatment of solid tumors and blosozumab (TST002) for the treatment of osteoporosis. The stock short name change will further enhance the Company’s global brand identity and market recognition, strengthen stakeholders’ understanding of the Company as a specialized and global biopharmaceutical enterprise, and is in the best interests of the Company and its shareholders.

CHANGE OF COMPANY LOGO

The Board further announces that, with effect from 8 April 2026, the Company has adopted a new logo. The Company's former and new logos are set out below:



Former logo



New logo

The new logo will be printed on the Company's relevant corporate documents, including but not limited to interim and annual reports, announcements, circulars, notices, share certificates and press releases, and will be displayed on the Company's website (www.transcenta.com).

The change of stock short name and the logo of the Company will not affect any rights of the existing holders of securities of the Company or the Group's daily business operation and its financial position. All existing share certificates of the Company in issue bearing the former logo of the Company will continue to be evidence of title to such shares of the Company and will continue to be valid for trading, settlement, registration and delivery purposes. There will not be any arrangement for free exchange of the existing share certificates of the Company for new share certificates bearing the new logo of the Company.

All new share certificates of the Company will be issued under the new logo of the Company with effect from 8 April 2026.

By Order of the Board
Transcenta Holding Limited
Xueming Qian
*Executive Director, Chairman and
Chief Executive Officer*

Hong Kong, 8 April 2026

As at the date of this announcement, the Board comprises Dr. Xueming Qian as executive director, chairman and chief executive officer, Dr. Li Xu as non-executive director and Mr. Jiasong Tang, Mr. Zhihua Zhang, Dr. Kumar Srinivasan and Ms. Helen Wei Chen as independent non-executive directors.